MIOKARD INFARKTIDAN KEYINGI HUJAYRAVIY TERAPIYANING ZAMONAVIY YONDASHUVLARI VA ISTIQBOLLARI

Article Sidebar

PDF
Выпуск: Том 4 № 15 : Естественные науки в современном мире: теоретические и практические исследования
Раздел: Статьи
Опубликован:

Main Article Content

Normal va patologik fiziologiya kafedrasi o’qituvchisi
m.aysacheva@gmail.com
Qoʻqon universiteti Andijon filiali Davolash ishi yoʻnalishi 24_04-guruh talabalari
gulrangbegimrustambekova154@gmail.com
Qoʻqon universiteti Andijon filiali Davolash ishi yoʻnalishi 24_04-guruh talabalari
muxlisapulatova58@gmail.com

Аннотация:

Miokard infarktidan keyingi hujayraviy terapiya yurak mushaklarining qayta tiklanishi va funksional faoliyatini yaxshilashda istiqbolli yondashuvlardan biri hisoblanadi. Zamonaviy tadqiqotlar ko‘rsatadiki, ildiz hujayralar, gen terapiyasi va biomaterial asosidagi regenerativ texnologiyalar yurak to‘qimalarida remodellasiyani kamaytirish, angiogenezni kuchaytirish hamda kardiomiositlarning hayotiyligini oshirishda muhim rol o‘ynaydi. Klinik tajribalar shuni ko‘rsatadiki, turli hujayra manbalari mezenximal ildiz hujayralar, iPS-hujayralar, yurakdan olingan progenitor hujayralar turlicha samaradorlikka ega bo‘lib, ularning kombinatsiyalangan qo‘llanilishi yanada yuqori natijalar berishi mumkin. Shu bilan birga, hujayralarni yetkazib berish usullari intrakoronar, intramiyokardial, biomaterial karkaslar orqali terapiyaning samaradorligini belgilovchi asosiy omillardan biridir. Kelajak istiqbollari sifatida hujayraviy terapiyani gen muhandisligi, nano-biotexnologiya va sun’iy intellekt yordamida optimallashtirish, shuningdek, personalizatsiyalangan yondashuvlarni ishlab chiqish kutilmoqda. Ushbu maqola miokard infarktidan keyingi hujayraviy terapiyaning zamonaviy yondashuvlari, mexanizmlari va klinik istiqbollarini tahlil qiladi.

Ключевые слова:

Article Details

Как цитировать:

Aysacheva , M. ., Rustambekova , G. ., & Pulatova , M. . (2025). MIOKARD INFARKTIDAN KEYINGI HUJAYRAVIY TERAPIYANING ZAMONAVIY YONDASHUVLARI VA ISTIQBOLLARI. Естественные науки в современном мире: теоретические и практические исследования, 4(15), 124–127. извлечено от https://in-academy.uz/index.php/zdtf/article/view/70188

Библиографические ссылки:

Hausenloy DJ, Yellon DM. Myocardial ischemia–reperfusion injury: a neglected therapeutic target. New England Journal of Medicine. 2013;369(20):1951–1952.

Frangogiannis NG. Pathophysiology of myocardial infarction. Circulation Research. 2015;116(5):844–857.

Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324(5923):98–102.

Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circulation Research. 2008;103(11):1204–1219.

Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow–derived progenitor cells in acute myocardial infarction (REPAIR-AMI). New England Journal of Medicine. 2006;355(12):1210–1221.

Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST trial. The Lancet. 2004;364(9429):141–148.

Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous mesenchymal stem cells for cardiac repair (POSEIDON trial). JAMA. 2012;308(22):2369–2379.

Bolli R, Chugh AR, D’Amario D, et al. Cardiac stem cells in patients with ischemic cardiomyopathy (SCIPIO). The Lancet. 2011;378(9806):1847–1857.

Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS). The Lancet. 2012;379(9819):895–904.

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse fibroblasts by defined factors. Cell. 2006;126(4):663–676.

Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Nature Reviews Cardiology. 2015;12(7):402–412.